HCA Healthcare (HCA) Projected to Post Earnings on Friday

HCA Healthcare (NYSE:HCA) is projected to post its Q1 2026 results before the market opens on Friday, April 24th. Analysts expect HCA Healthcare to post earnings of $7.19 per share and revenue of $19.0861 billion for the quarter. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, April 24, 2026 at 10:00 AM ET.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, topping analysts’ consensus estimates of $7.37 by $0.64. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The company had revenue of $19.51 billion during the quarter, compared to analyst estimates of $19.67 billion. During the same period in the previous year, the company earned $6.22 earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, analysts expect HCA Healthcare to post $30 EPS for the current fiscal year and $33 EPS for the next fiscal year.

HCA Healthcare Stock Down 1.5%

Shares of HCA stock opened at $471.20 on Wednesday. HCA Healthcare has a 12 month low of $317.54 and a 12 month high of $556.52. The firm has a market cap of $105.35 billion, a PE ratio of 16.60, a price-to-earnings-growth ratio of 1.47 and a beta of 1.36. The stock has a 50 day moving average of $509.99 and a 200-day moving average of $485.23.

HCA Healthcare Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th were paid a $0.78 dividend. The ex-dividend date was Tuesday, March 17th. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare’s dividend payout ratio is currently 10.99%.

Analysts Set New Price Targets

HCA has been the subject of a number of recent research reports. Argus upped their target price on HCA Healthcare from $530.00 to $560.00 and gave the company a “buy” rating in a research note on Friday, February 6th. TD Cowen upped their target price on HCA Healthcare from $529.00 to $561.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Mizuho upped their target price on HCA Healthcare from $540.00 to $585.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft upped their target price on HCA Healthcare from $500.00 to $558.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Finally, Sanford C. Bernstein set a $541.00 price objective on HCA Healthcare in a research note on Monday, February 9th. Sixteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, HCA Healthcare has an average rating of “Moderate Buy” and a consensus target price of $537.36.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 1,500 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $498.09, for a total transaction of $747,135.00. Following the sale, the executive vice president owned 30,003 shares in the company, valued at approximately $14,944,194.27. This represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Christopher F. Wyatt sold 4,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total value of $2,020,000.00. Following the sale, the senior vice president owned 44,379 shares in the company, valued at $22,411,395. The trade was a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 15,214 shares of company stock valued at $7,797,595. 1.50% of the stock is owned by insiders.

Institutional Trading of HCA Healthcare

Large investors have recently made changes to their positions in the business. Palisade Asset Management LLC bought a new stake in shares of HCA Healthcare during the third quarter worth $26,000. JPL Wealth Management LLC bought a new position in HCA Healthcare in the third quarter valued at about $33,000. Greenline Wealth Management LLC bought a new position in HCA Healthcare in the fourth quarter valued at about $42,000. EFG International AG bought a new position in HCA Healthcare in the fourth quarter valued at about $44,000. Finally, Triumph Capital Management bought a new position in HCA Healthcare in the third quarter valued at about $51,000. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.